GRCE GRCE
Company Profile ↓Company Overview
GRCE (GRCE) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 50920.4% CAGR over the past five years.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR 50920.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 50,920.41% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -28.67% |
| 6 Months: | -42.32% |
| 3 Months: | -8.15% |
| 1 Month: | -14.74% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 50920.4% over 5 years.
CONS
- Trading 58.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Jun 2021 | Sep 2021 | Dec 2021 | Jun 2022 | Sep 2022 | Dec 2022 | Jun 2023 | Sep 2023 | Dec 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 81.00K | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -8.01M | -6.25M | -6.15M | - | -4.12M | -8.03M | -1.96M | -3.15M | -3.57M | -4.47M | -4.73M | -5.11M | -4.25M | -4.45M | -2.09M | -3.04M | -4.96M | -4.83M | -3.70M | -3.09M | -2.53M | -2.45M |
| Net Income | -39.37M | -8.85M | -21.16M | -12.12M | -25.51M | -4.67M | -6.15M | -3.22M | -3.12M | 981.00K | -3.78M | -4.52M | -4.93M | -3.89M | -4.02M | -3.27M | -2.39M | -2.62M | -3.43M | -4.16M | -3.36M | -938.00K | -2.31M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.12 | -0.03 | -0.09 | -0.61 | -0.66 | -0.52 | -0.54 | -0.43 | -0.21 | -0.24 | -0.30 | -0.36 | -0.21 | -0.06 | -0.14 |
| R&D Expense | - | 6.19M | 3.95M | 3.91M | - | 1.76M | 1.29M | 678.00K | 469.00K | 585.00K | 2.18M | 2.59M | 3.29M | 2.45M | 1.09M | 460.00K | 1.44M | 2.71M | 2.98M | 2.19M | 955.00K | 568.00K | 462.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 196.00K | 100.00M | - | - | - | - |
| Operating Income | -34.41M | -24.44M | -16.42M | -15.59M | -52.16M | -12.85M | -16.68M | -11.08M |
| Net Income | -39.37M | -25.51M | -19.68M | -9.82M | -42.43M | -12.85M | -9.57M | -7.79M |
| Diluted EPS | - | - | - | -0.27 | -5.71 | -1.35 | -0.79 | -0.47 |
| R&D Expense | 29.37M | 15.97M | 4.17M | 5.56M | 9.97M | 4.68M | 9.51M | 2.40M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2018 | Dec 2018 | Mar 2019 | Dec 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 36.90M | - | 22.85M | 62.46M | 128.62M | 79.12M | 73.30M | 71.99M | 66.65M |
| Total Equity | 7.19M | - | 11.04M | - | 12.99M | 55.66M | 108.27M | 67.95M | 61.74M | 66.61M | 63.90M |
| Cash & Equivalents | - | 6.42M | 16.87M | 16.87M | 14.24M | 50.94M | 30.34M | 27.88M | 23.00M | 22.13M | 16.98M |
| Total Liabilities | - | - | 25.85M | - | 9.86M | 6.80M | 20.35M | 11.17M | 11.56M | 5.38M | 2.76M |
| Current Liabilities | - | - | 13.67M | - | 7.39M | 1.58M | 3.26M | 3.41M | 1.68M | 1.93M | 2.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -22.95M | -14.32M | -17.23M | -15.91M | -12.33M | -14.90M | -8.87M |
| Investing Cash Flow | 8.14M | -9.86M | -3.52M | 13.15M | 104.00K | 0 | 0 |
| Financing Cash Flow | 13.18M | 59.49M | 0 | 304.00K | 7.36M | 14.03M | 3.71M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -8,377.0% | -15.6% | - | - | - | - |
| Net Margin % | - | - | -10,039.8% | -9.8% | - | - | - | - |
| ROE % | -356.4% | -196.3% | -35.4% | -9.1% | -62.4% | -20.8% | -14.4% | -12.2% |
| ROCE % | -148.1% | -158.1% | -27.0% | -12.4% | -68.9% | -17.9% | -23.8% | -17.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GRCE
Grace Therapeutics Expects Funding to Extend Cash Runway Through 2028 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNZUxyb1Q0THk2VzdRdlBwQmsybzRXeFBCaE1zSUJCWVdVVG5OZW9FR1NZRENwVHFlY3Z2Y1dQZXZPeGRPQV9UUm9Qamo2SUtZSzZONnpEeE1MSW13TmNBNVhQdEFZWHBuOHdWQ01aYWdZREpLeVhJY2dhZGw3WVVXQm1Oek45VF9MUmtHcF…
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNVDBvanlnSDJaeXItSjF0UlByQ0w1SUlLYVJRYVJlNnFZLWtpWVJ4YzE0RTFhbE42c0FnclZvLVdyY2lBVEJ5eFhXTlVnWk12RFhnYzNMRmZpYmtWMFd6c29OZFFsSXBPMGhfT2VVRW1aLTEwOXp4T0VVY3dQa1IzNjcxamVOU2pxc2J1QW…
Grace Therapeutics (GRCE) Raises $10M in Private Placement Amid High Price-to-Sales Valuation - GuruFocus
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQbmM4MVUwLXdhWWFoa1A3TGNKVGVPR3VTNGl3THRZM1RlNmdDcVd3b1RYVVB1RW5lcGxBb3pzYmUtZENpUFNURTl4bzIxZzBzZHE4UFdDQmowVGtGbmNqa3pSckdJTFdINXgyeWFMQ09uNVI5VjNuMWt3X0l4bFo2ZHkyMDY0NFRKRi1tY1…
Grace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQMFNlTU55N2Y0bUhSOHdJX2lvVGExSHNkNlFxUmhiNjVnRHd3ZTJGY1lRLU82WVhjb1M3ME5CajNUTko3M3ZRektRSVE1cVpvRHZSdTBtR01ObE54UllaZWZ5X3o5NkdJV0JUY2l0QzFTRW1OSUJCc2JxNTBfWnZYdTc1Zmg2QmJOZlFjSU…
We're Not Very Worried About Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxNdlhsWXI0UHlvdl9PUTRvRjlTNDJyS3o5WTlyWXRPWGZPRFFuc0lwbWhXak5laVZGaWg4ZzhZTkN4WW1Kc0podWx4eV9OaDBHdjdNMmtUT2kwU3ZmMFJGQk5NUk5CM24ybTh5eUZTQTlNRWtQQTNVMUN2RXMxVjFZdm9PN1FCR1RRTy1EMT…
GRCE Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE54WHpBX2NiWHlyeDlTeU5WNWJOcHlFSkVZZTUwM1dTY0xKZzYwdlFVMXo5WTEyM2VHLXVuc05QdjU3RWgxRmthamt2WldXa0JTZURMaTlsa2h5VV8wVnB1U2F1SVVUQnBPcks0c3plbXA0QUhQQnhFcXh3?oc=5" target="_blank">GRC…
GRCE — Frequently Asked Questions
What is the current share price of GRCE?
As of 2026-08-05 17:25 PDT, GRCE trades at $2.14 on NASDAQ/NYSE. Its 52-week range is $2.07 to $5.13.
What is the P/E ratio of GRCE?
GRCE trades at a trailing price-to-earnings (P/E) ratio of -4.55.
What is the return on equity (ROE) of GRCE?
GRCE has a return on equity (ROE) of -12.20%. Its return on capital employed (ROCE) is -17.17%.
Is GRCE a good stock to buy?
This page provides a data-driven analysis of GRCE, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.